Although this study suggests that radiobrominated 2 has more promising property for PET imaging of PDGFRβ than radioiodinated 4, in clinical application of the radiobrominated compound as a PDGFRβ-targeted PET imaging agent, structural modification would be required to improve tumor uptake and tumor-to-background ratios. Here, PDGFRB is linked to neoplasm.